Nanomedicine approaches in acute lymphoblastic leukemia

J Control Release. 2016 Sep 28:238:123-138. doi: 10.1016/j.jconrel.2016.07.035. Epub 2016 Jul 25.

Abstract

Acute lymphoblastic leukemia (ALL) is the malignancy with the highest incidence amongst children (26% of all cancer cases), being surpassed only by the cancers of the brain and of the nervous system. The most recent research on ALL is focusing on new molecular therapies, like targeting specific biological structures in key points in the cell cycle, or using selective inhibitors for transmembranary proteins involved in cell signalling, and even aiming cell surface receptors with specifically designed antibodies for active targeting. Nanomedicine approaches, especially by the use of nanoparticle-based compounds for the delivery of drugs, cancer diagnosis or therapeutics may represent new and modern ways in the near future anti-cancer therapies. This review offers an overview on the recent role of nanomedicine in the detection and treatment of acute lymphoblastic leukemia as resulting from a thorough literature survey. A short introduction on the basics of ALL is presented followed by the description of the conventional methods used in the ALL detection and treatment. We follow our discussion by introducing some of the general nano-strategies used for cancer detection and treatment. The detailed role of organic and inorganic nanoparticles in ALL applications is further presented, with a special focus on gold nanoparticle-based nanocarriers of antileukemic drugs.

Keywords: Acute lymphoblastic leukemia; Cancer therapy; Nanomedicine; Nanoparticles.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems / methods
  • Humans
  • Nanomedicine / methods*
  • Nanoparticles / chemistry
  • Nanoparticles / therapeutic use
  • Nanotechnology / methods
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Translational Research, Biomedical